The present disclosure relates to the field of endoscopy. Specifically, the present disclosure relates to systems and methods for delivering a therapeutic agent within a body lumen, and maintaining the therapeutic agent in contact with a wall of the body lumen for a beneficial period of time. In particular, the present disclosure relates to systems and methods to prevent lesions within the gastrointestinal tract from spreading into healthy surrounding tissue.

A customizable drug delivery system and method utilizing a laser pattern generator (LPG) to define application of a drug delivery payload (DDP) contained within a drug delivery device (DDD) to a drug delivery target (DDT) is disclosed. A computer control device (CCD) supervises the LPG to select a drug payload pathway (DPP) from a drug pathway database (DPD) and writes the selected DPP to the DDD. This pathway patterning process (PPP) modifies the hydrophilic properties of the DDD and enables the DDD to selectively attract and absorb the DDP. The DDD is then injected with the DDP or exposed for drug exposure time (DET) by the CCD and DPD during which the DPP written to the DDD absorbs a controlled amount of DDP. The DDD when subsequently inserted into a drug delivery target (DDT) delivers the DDP to the DDT under controlled delivery rates defined by the DPP and the DET.

Various embodiments are described herein for an ocular device implantable in a user's eye and which has an adjustable optical element for varying one or more optical properties for the eye such as, but not limited to, providing a dynamically adjustable aperture stop to control the amount of incoming light, filtering incoming light, polarizing incoming light, and/or varying a depth of field for the eye.

A prosthetic capsular device configured to be inserted in an eye includes a housing structure and a ring structure. The housing structure includes a first side, a second side opposite the first side, a third side, a fourth side opposite the third side, a posterior side including a refractive surface, an anterior side opposite the posterior side, and a longitudinal axis. The first side, the second side, the third side, the fourth side, the posterior side, and the anterior side at least partially define a cavity configured to contain an intraocular device (e.g., an IOL). The anterior side includes an opening. The ring structure includes a ring structure portion extending radially outward from proximate one of an end of the first side and an end of the second side.

A degradation data generator is used with a scaffold for delivery within a patient. The degradation data generator includes a driving circuit electrically coupled to drive an impedance of the scaffold. A detection circuit generates degradation data based on the impedance of the scaffold or other properties such as RF or lightwave transmission, conductance or absorption. The degradation data indicates an amount of biodegradation of the scaffold. A wireless transmitter is coupled to transmit the degradation data to a wireless degradation data receiver, while the scaffold is within the patient.

Disclosed herein are drug delivery punctal implants and methods of using the implants for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The physical arrangement of drugs within the punctal plugs disclosed herein results, in several embodiments, in advantageous controlled delivery of one or more drugs to the eye of a patient.

A combination bioactive silicate (e.g., bioactive glass) medicine carrier and shunt of one embodiment includes a shunt which is a tubular member made of bioactive silicate or glass being adapted to be bioresorbable and water soluble, or fiber bundle, the shunt including an insertion end at a first end. Gaps in the bioactive silicate or gaps in the glass adapted to be bioresorbable and water soluble are served as at least one storage for storing medicines.

A prosthetic capsular device configured to be inserted in an eye includes a housing structure and a ring structure. The housing structure includes a first side, a second side opposite the first side, a third side, a fourth side opposite the third side, a posterior side including a refractive surface, an anterior side opposite the posterior side, and a longitudinal axis. The first side, the second side, the third side, the fourth side, the posterior side, and the anterior side at least partially define a cavity configured to contain an intraocular device (e.g., an IOL). The anterior side includes an opening. The ring structure includes a ring structure portion extending radially outward from proximate one of an end of the first side and an end of the second side.

An implantable device for scheduled intraocular drug delivery comprising at least two hollow solids inscribed one into the other, where the walls of said at least two hollow solids are made of biodegradable material based on magnesium, and where said at least two hollow solids inscribed one into the other delimit a volume, called core, inside the innermost of said hollow solids and one or more volumes, called cores, comprised between said innermost hollow solid and the hollow solid at the exterior thereof, where said core and said at least one crown are adapted to house doses of at least one active ingredient, characterized in that said walls are impermeable continuous walls which become permeable as a function of the post-implantation time of said device.

An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.